We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MeMed Ltd., a leader in host response-based diagnostic solutions, today announced that it has received €2.5 million in non-dilutive funding from the European Innovation Council (EIC).
Israeli diagnostics player MeMed reported data from a study of more than 500 children and adolescents showing that its blood test can accurately tell the difference between a bacterial and a viral infection.